Integrating transcriptomics and metabonomics to unravel modes-of-action of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in HepG2 cells

BMC Systems Biology

Volumn 5, Issue , 2011, Pages

  Jennen, Danyel ^a,c   Ruiz Aracama, Ainhoa ^b,c   Magkoufopoulou, Christina ^a   Peijnenburg, Ad ^b,c   Lommen, Arjen ^b,c   van Delft, Joost ^a,c   Kleinjans, Jos ^a,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c Netherlands Toxicogenomics Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; CARCINOGEN;

ARTICLE; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; METHODOLOGY; SYSTEMS BIOLOGY; TUMOR CELL LINE;

CARCINOGENS, ENVIRONMENTAL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HUMANS; METABOLIC NETWORKS AND PATHWAYS; SYSTEMS BIOLOGY; TETRACHLORODIBENZODIOXIN;

EID: 80052178654     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-5-139     Document Type: Article

References (83)

1. MAQC The MicroArray Quality Control Consortium. Nature Biotechnology 2006, 24:1039-1169. MAQC.
2. Ellinger-Ziegelbauer H, Gmuender H, Bandenburg A, Ahr HJ. Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat Res 2008, 637:23-39. 10.1016/j.mrfmmm.2007.06.010, 17689568.
3. Fielden MR, Brennan R, Gollub J. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol Sci 2007, 99:90-100. 10.1093/toxsci/kfm156, 17557906.
4. Nie AY, McMillian M, Parker JB, Leone A, Bryant S, Yieh L, Bittner A, Nelson J, Carmen A, Wan J, Lord PG. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol Carcinog 2006, 45:914-933. 10.1002/mc.20205, 16921489.
5. van Delft JH, van Agen E, van Breda SG, Herwijnen MH, Staal YC, Kleinjans JC. Discrimination of genotoxic from non-genotoxic carcinogens by gene expression profiling. Carcinogenesis 2004, 25:1265-1276. 10.1093/carcin/bgh108, 14963013.
6. van Delft JH, van Agen E, van Breda SG, Herwijnen MH, Staal YC, Kleinjans JC. Comparison of supervised clustering methods to discriminate genotoxic from non-genotoxic carcinogens by gene expression profiling. Mutat Res 2005, 575:17-33. 10.1016/j.mrfmmm.2005.02.006, 15924884.
7. Woods CG, Kosyk O, Bradford BU, Ross PK, Burns AM, Cunningham ML, Qu P, Ibrahim JG, Rusyn I. Time course investigation of PPARalpha- and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expression. Toxicol Appl Pharmacol 2007, 225:267-277. 10.1016/j.taap.2007.08.028, 2153436, 17950772.
8. Boverhof DR, Burgoon LD, Tashiro C, Sharratt B, Chittim B, Harkema JR, Mendrick DL, Zacharewski TR. Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in Sprague Dawley rats and C57BL/6 mice. Toxicol Sci 2006, 94:398-416. 10.1093/toxsci/kfl100, 16960034.
9. Dere E, Boverhof DR, Burgoon LD, Zacharewski TR. In vivo-in vitro toxicogenomic comparison of TCDD-elicited gene expression in Hepa1c1c7 mouse hepatoma cells and C57BL/6 hepatic tissue. BMC Genomics 2006, 7:80. 10.1186/1471-2164-7-80, 1513214, 16611356.
10. Kim S, Dere E, Burgoon LD, Chang CC, Zacharewski TR. Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicol Sci 2009, 112:229-244. 10.1093/toxsci/kfp189, 2769060, 19684285.
11. Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004, 9:1-31. 10.1080/13547500410001668379, 15204308.
12. van Ravenzwaay B, Cunha GC, Leibold E, Looser R, Mellert W, Prokoudine A, Walk T, Wiemer J. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett 2007, 172:21-28. 10.1016/j.toxlet.2007.05.021, 17614222.
13. Coen M, Holmes E, Lindon JC, Nicholson JK. NMR-Based Metabolic Profiling and Metabonomic Approaches to Problems in Molecular Toxicology. Chem Res Toxicol 2008, 21:9-27. 10.1021/tx700335d, 18171018.
14. Robertson DG. Metabonomics in toxicology: a review. Toxicol Sci 2005, 85:809-822. 10.1093/toxsci/kfi102, 15689416.
15. Coen M, Ruepp SU, Lindon JC, Nicholson JK, Pognan F, Lenz EM, Wilson ID. Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. J Pharm Biomed Anal 2004, 35:93-105. 10.1016/j.jpba.2003.12.019, 15030884.
16. Craig A, Sidaway J, Holmes E, Orton T, Jackson D, Rowlinson R, Nickson J, Tonge R, Wilson I, Nicholson J. Systems toxicology: integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. J Proteome Res 2006, 5:1586-1601. 10.1021/pr0503376, 16823966.
17. Heijne WH, Lamers RJ, van Bladeren PJ, Groten JP, van Nesselrooij JH, van Ommen B. Profiles of metabolites and gene expression in rats with chemically induced hepatic necrosis. Toxicol Pathol 2005, 33:425-433. 10.1080/01926230590958146, 16036859.
18. Kleno TG, Kiehr B, Baunsgaard D, Sidelmann UG. Combination of 'omics' data to investigate the mechanism(s) of hydrazine-induced hepatotoxicity in rats and to identify potential biomarkers. Biomarkers 2004, 9:116-138. 10.1080/13547500410001728408, 15370871.
19. Toye AA, Dumas ME, Blancher C, Rothwell AR, Fearnside JF, Wilder SP, Bihoreau MT, Cloarec O, Azzouzi I, Young S, et al. Subtle metabolic and liver gene transcriptional changes underlie diet-induced fatty liver susceptibility in insulin-resistant mice. Diabetologia 2007, 50:1867-1879. 10.1007/s00125-007-0738-5, 17618414.
20. Collins FS, Gray GM, Bucher JR. Toxicology. Transforming environmental health protection. Science 2008, 319:906-907. 10.1126/science.1154619, 2679521, 18276874.
21. IARC IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Polychlorinated Dibenzo-Para-Dioxins and Polychlorinated Dibenzofurans. Lyon, France, 4-11 February 1997. IARC Monogr Eval Carcinog Risks Hum 1997, 69:1-631. IARC.
22. NTP NTP 11th Report on Carcinogens. Rep Carcinog 2005, 1-A32. NTP.
23. Sorg O, Zennegg M, Schmid P, Fedosyuk R, Valikhnovskyi R, Gaide O, Kniazevych V, Saurat JH. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) poisoning in Victor Yushchenko: identification and measurement of TCDD metabolites. Lancet 2009, 374:1179-1185. 10.1016/S0140-6736(09)60912-0, 19660807.
24. Christian BJ, Menahan LA, Peterson RE. Intermediary metabolism of the mature rat following 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment. Toxicol Appl Pharmacol 1986, 83:360-378. 10.1016/0041-008X(86)90313-3, 3961820.
25. Geusau A, Abraham K, Geissler K, Sator MO, Stingl G, Tschachler E. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: clinical and laboratory effects. Environ Health Perspect 2001, 109:865-869. 10.1289/ehp.01109865, 1240417, 11564625.
26. Jahns GL, Kent MN, Burgoon LD, DelRaso N, Zacharewski TR, Reo NV. Development of analytical methods for NMR spectra and application to a 13C toxicology study. Metabolomics 2009, 5:253-262.
27. Lakshman MR, Chirtel SJ, Chambers LL, Coutlakis PJ. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on lipid synthesis and lipogenic enzymes in the rat. J Pharmacol Exp Ther 1989, 248:62-66.
28. Thomas T, MacKenzie SA, Gallo MA. Regulation of polyamine biosynthesis by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Lett 1990, 53:315-325. 10.1016/0378-4274(90)90236-F, 2237938.
29. Viluksela M, Unkila M, Pohjanvirta R, Tuomisto JT, Stahl BU, Rozman KK, Tuomisto J. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on liver phosphoenolpyruvate carboxykinase (PEPCK) activity, glucose homeostasis and plasma amino acid concentrations in the most TCDD-susceptible and the most TCDD-resistant rat strains. Arch Toxicol 1999, 73:323-336. 10.1007/s002040050626, 10447560.
30. Burczynski ME, McMillian M, Ciervo J, Li L, Parker JB, Dunn RT, Hicken S, Farr S, Johnson MD. Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol Sci 2000, 58:399-415. 10.1093/toxsci/58.2.399, 11099651.
31. Harries HM, Fletcher ST, Duggan CM, Baker VA. The use of genomics technology to investigate gene expression changes in cultured human liver cells. Toxicol In Vitro 2001, 15:399-405. 10.1016/S0887-2333(01)00043-1, 11566570.
32. Hong Y, Muller UR, Lai F. Discriminating two classes of toxicants through expression analysis of HepG2 cells with DNA arrays. Toxicol In Vitro 2003, 17:85-92. 10.1016/S0887-2333(02)00122-4, 12537966.
33. Rudzok S, Schlink U, Herbarth O, Bauer M. Measuring and modeling of binary mixture effects of pharmaceuticals and nickel on cell viability/cytotoxicity in the human hepatoma derived cell line HepG2. Toxicol Appl Pharmacol 2010, 244:336-343. 10.1016/j.taap.2010.01.012, 20132835.
34. Guo L, Dial S, Shi L, Branham W, Liu J, Fang JL, Green B, Deng H, Kaput J, Ning B. Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes. Drug Metab Dispos 2010, 39:528-538.
35. Jennen DG, Gaj S, Giesbertz PJ, van Delft JH, Evelo CT, Kleinjans JC. Biotransformation pathway maps in WikiPathways enable direct visualization of drug metabolism related expression changes. Drug Discov Today 2010, 15:851-858. 10.1016/j.drudis.2010.08.002, 20708095.
36. Misaki K, Matsui S, Matsuda T. Metabolic enzyme induction by HepG2 cells exposed to oxygenated and nonoxygenated polycyclic aromatic hydrocarbons. Chem Res Toxicol 2007, 20:277-283. 10.1021/tx060197u, 17253728.
37. Westerink WM, Schoonen WG. Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 2007, 21:1592-1602. 10.1016/j.tiv.2007.06.017, 17716855.
38. Westerink WM, Schoonen WG. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 2007, 21:1581-1591. 10.1016/j.tiv.2007.05.014, 17637504.
39. van Delft JH, Mathijs K, Staal YC, van Herwijnen MH, Brauers KJ, Boorsma A, Kleinjans JC. Time series analysis of benzo[A]pyrene-induced transcriptome changes suggests that a network of transcription factors regulates the effects on functional gene sets. Toxicol Sci 2010, 117:381-392. 10.1093/toxsci/kfq214, 20624995.
40. Jennen DG, Magkoufopoulou C, Ketelslegers HB, van Herwijnen MH, Kleinjans JC, van Delft JH. Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci 2010, 115:66-79. 10.1093/toxsci/kfq026, 20106945.
41. Boutros PC, Yan R, Moffat ID, Pohjanvirta R, Okey AB. Transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in liver: comparison of rat and mouse. BMC Genomics 2008, 9:419. 10.1186/1471-2164-9-419, 2559853, 18796159.
42. Ruiz-Aracama A, Peijnenburg A, Kleinjans J, Jennen D, van Delft J, Hellfrisch C, Lommen A. An untargeted multi-technique metabolomics approach to studying intracellular metabolites of HepG2 cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. BMC Genomics 2011, 12:251. 10.1186/1471-2164-12-251, 3141663, 21599895.
43. Gehlenborg N, O'Donoghue SI, Baliga NS, Goesmann A, Hibbs MA, Kitano H, Kohlbacher O, Neuweger H, Schneider R, Tenenbaum D, Gavin AC. Visualization of omics data for systems biology. Nat Methods 2010, 7:S56-68. 10.1038/nmeth.1436, 20195258.
44. Silva Lima B, Van der Laan JW. Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. Regul Toxicol Pharmacol 2000, 32:135-143. 10.1006/rtph.2000.1427, 11067770.
45. Knerr S, Schaefer J, Both S, Mally A, Dekant W, Schrenk D. 2,3,7,8-Tetrachlorodibenzo-p-dioxin induced cytochrome P450s alter the formation of reactive oxygen species in liver cells. Mol Nutr Food Res 2006, 50:378-384. 10.1002/mnfr.200500183, 16534750.
46. Reichard JF, Dalton TP, Shertzer HG, Puga A. Induction of Oxidative Stress Responses by Dioxin and other Ligands of the Aryl Hydrocarbon Receptor. Dose Response 2005, 3:306-331.
47. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res 2005, 575:61-84. 10.1016/j.mrfmmm.2005.02.004, 15890375.
48. Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 1999, 31:273-300. 10.1080/10715769900300851, 10517533.
49. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr 2004, 134:489-492.
50. Senft AP, Dalton TP, Nebert DW, Genter MB, Hutchinson RJ, Shertzer HG. Dioxin increases reactive oxygen production in mouse liver mitochondria. Toxicol Appl Pharmacol 2002, 178:15-21. 10.1006/taap.2001.9314, 11781075.
51. Senft AP, Dalton TP, Nebert DW, Genter MB, Puga A, Hutchinson RJ, Kerzee JK, Uno S, Shertzer HG. Mitochondrial reactive oxygen production is dependent on the aromatic hydrocarbon receptor. Free Radic Biol Med 2002, 33:1268-1278. 10.1016/S0891-5849(02)01014-6, 12398935.
52. Aly HA, Domenech O. Cytotoxicity and mitochondrial dysfunction of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in isolated rat hepatocytes. Toxicol Lett 2009, 191:79-87. 10.1016/j.toxlet.2009.08.008, 19686823.
53. Lin PH, Lin CH, Huang CC, Chuang MC, Lin P. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines. Toxicol Lett 2007, 172:146-158. 10.1016/j.toxlet.2007.06.003, 17669606.
54. Shertzer HG, Genter MB, Shen D, Nebert DW, Chen Y, Dalton TP. TCDD decreases ATP levels and increases reactive oxygen production through changes in mitochondrial F(0)F(1)-ATP synthase and ubiquinone. Toxicol Appl Pharmacol 2006, 217:363-374. 10.1016/j.taap.2006.09.014, 1783833, 17109908.
55. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465. 10.1038/nrc1097, 12778136.
56. Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci 2005, 118:843-846. 10.1242/jcs.01660, 15731001.
57. Park R, Kim DH, Kim MS, So HS, Chung HT, Kwon KB, Ryu DG, Kim BR. Association of Shc, Cbl, Grb2, and Sos following treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin in primary rat hepatocytes. Biochem Biophys Res Commun 1998, 253:577-581. 10.1006/bbrc.1998.9816, 9918770.
58. Pierre S, Bats AS, Chevallier A, Bui LC, Ambolet-Camoit A, Garlatti M, Aggerbeck M, Barouki R, Coumoul X. Induction of the Ras activator Son of Sevenless 1 by environmental pollutants mediates their effects on cellular proliferation. Biochem Pharmacol 2011, 81:304-313. 10.1016/j.bcp.2010.10.003, 20950586.
59. Wu G, Bazer FW, Davis TA, Kim SW, Li P, Marc Rhoads J, Carey Satterfield M, Smith SB, Spencer TE, Yin Y. Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009, 37:153-168. 10.1007/s00726-008-0210-y, 2677116, 19030957.
60. Wiame E, Tyteca D, Pierrot N, Collard F, Amyere M, Noel G, Desmedt J, Nassogne MC, Vikkula M, Octave JN, et al. Molecular identification of aspartate N-acetyltransferase and its mutation in hypoacetylaspartia. Biochem J 2010, 425:127-136.
61. Mehta V, Namboodiri MA. N-acetylaspartate as an acetyl source in the nervous system. Brain Res Mol Brain Res 1995, 31:151-157.
62. Lourenco R, Camilo ME. Taurine: a conditionally essential amino acid in humans? An overview in health and disease. Nutr Hosp 2002, 17:262-270.
63. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003, 72:137-174. 10.1146/annurev.biochem.72.121801.161712, 12543708.
64. Yanagita T, Han SY, Hu Y, Nagao K, Kitajima H, Murakami S. Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells. Lipids Health Dis 2008, 7:38. 10.1186/1476-511X-7-38, 2579289, 18925970.
65. Park SH, Lee H, Park KK, Kim HW, Park T. Taurine-responsive genes related to signal transduction as identified by cDNA microarray analyses of HepG2 cells. J Med Food 2006, 9:33-41. 10.1089/jmf.2006.9.33, 16579726.
66. Seiler N, Raul F. Polyamines and apoptosis. J Cell Mol Med 2005, 9:623-642. 10.1111/j.1582-4934.2005.tb00493.x, 16202210.
67. Moinard C, Cynober L, de Bandt JP. Polyamines: metabolism and implications in human diseases. Clin Nutr 2005, 24:184-197. 10.1016/j.clnu.2004.11.001, 15784477.
68. Casero RA, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007, 6:373-390. 10.1038/nrd2243, 17464296.
69. Minuk GY. GABA and hepatocellular carcinoma. Mol Cell Biochem 2000, 207:105-108. 10.1023/A:1007062802164, 10888234.
70. Kleinrok Z, Matuszek M, Jesipowicz J, Matuszek B, Opolski A, Radzikowski C. GABA content and GAD activity in colon tumors taken from patients with colon cancer or from xenografted human colon cancer cells growing as s.c. tumors in athymic nu/nu mice. J Physiol Pharmacol 1998, 49:303-310.
71. Matuszek M, Jesipowicz M, Kleinrok Z. GABA content and GAD activity in gastric cancer. Med Sci Monit 2001, 7:377-381.
72. Barany M, Langer BG, Glick RP, Venkatasubramanian PN, Wilbur AC, Spigos DG. In vivo H-1 spectroscopy in humans at 1.5 T. Radiology 1988, 167:839-844.
73. Bell JD, Cox IJ, Sargentoni J, Peden CJ, Menon DK, Foster CS, Watanapa P, Iles RA, Urenjak J. A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver. Biochim Biophys Acta 1993, 1225:71-77.
74. Cao Y, Sundgren PC, Tsien CI, Chenevert TT, Junck L. Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 2006, 24:1228-1235. 10.1200/JCO.2005.04.7233, 16525177.
75. Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, Lin D. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci 2009, 100:782-785. 10.1111/j.1349-7006.2009.01086.x, 19469021.
76. McConnell JR. Reduced levels of N-acetylaspartate in malignant brain tumors. CA Cancer J Clin 1999, 49:192. 10.3322/canjclin.49.3.192, 10445018.
77. Hockley SL, Arlt VM, Brewer D, Te Poele R, Workman P, Giddings I, Phillips DH. AHR- and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines. Chem Res Toxicol 2007, 20:1797-1810. 10.1021/tx700252n, 17944540.
78. Puga A, Maier A, Medvedovic M. The transcriptional signature of dioxin in human hepatoma HepG2 cells. Biochem Pharmacol 2000, 60:1129-1142. 10.1016/S0006-2952(00)00403-2, 11007951.
79. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005, 33:e175. 10.1093/nar/gni179, 1283542, 16284200.
80. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264. 10.1093/biostatistics/4.2.249, 12925520.
81. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 1995, 57:289-300.
82. Lommen A, Weseman JM, Smith GO, Noteborn HPJM. On the detection of environmental effects on complex matrices combining off-line liquid chromatography and 1H-NMR. Biodegradation 1998, 9:513-525.
83. Lommen A. MetAlign: interface-driven, versatile metabolomics tool for hyphenated full-scan mass spectrometry data preprocessing. Anal Chem 2009, 81:3079-3086. 10.1021/ac900036d, 19301908.